Herpesviridae infectious disease

This early-stage trial tests a new shingles vaccine in 120 adults aged 40 and older. The main goal is to check safety and side effects at different doses, while also looking at how well the vaccine triggers an immune response. Participants receive either the vaccine or a placebo,…

This study tests a new shingles vaccine called Z-1018 in about 764 healthy adults aged 50 and older. It compares Z-1018 to the current vaccine, Shingrix, to see if it is safe and triggers a strong immune response. The trial is in early phases (1 and 2), so the main focus is on sa…

This study tests an mRNA vaccine (mRNA-1647) to prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. About 84 participants will receive either the vaccine or a placebo. The goal is to see if the vaccine can safely prevent CMV after stopping stand…

This early-stage trial is testing a new mRNA vaccine called ABO1108 to prevent shingles in adults aged 40 and above. Around 180 healthy volunteers will receive two shots of either the new vaccine at different doses, a placebo, or the existing Shingrix vaccine. The main goal is to…

This phase II trial tests a vaccine designed to protect stem cell transplant recipients from cytomegalovirus (CMV), a common virus that can cause serious illness in people with weakened immune systems. The vaccine uses a modified, harmless virus to deliver three CMV proteins, tra…

This study tests a new mRNA vaccine called ABO1108 to see if it can prevent shingles in adults aged 40 and above. About 300 healthy volunteers will receive two shots, two months apart, and be compared to a placebo group. The goal is to measure the immune response and check for sa…

This study is testing an experimental mRNA vaccine called mRNA-1189 to see if it can safely prevent Epstein-Barr virus (EBV) infection in healthy people aged 10 to 30. EBV is a common virus that can cause mononucleosis and has been linked to some cancers. The vaccine is given as …

This study tests a new shingles vaccine called JCXH-105 in healthy adults aged 50 and older. It compares the new vaccine to the current standard, Shingrix, to see if it is safe and triggers a strong immune response. About 467 participants will receive either JCXH-105 or Shingrix,…

This study tests a new shingles vaccine in 960 healthy adults aged 40 and older. The goal is to see if it is safe and triggers a strong immune response. Researchers will monitor side effects and measure antibody levels over time. This is an early-stage trial to help develop a bet…

This Phase 3 trial is testing a new shingles vaccine in 12,000 adults aged 40 and older. The goal is to see if the vaccine can prevent shingles for up to 3 years after the two-dose series. Participants previously received the vaccine or a placebo, and researchers are tracking who…

This early-stage study is testing an mRNA vaccine designed to protect against genital herpes (HSV-2) in 144 healthy adults aged 18 to 55. The vaccine is given in different doses to people who have and have not been exposed to the virus before. The main goal is to check for side e…

This study tests a new shingles vaccine called LYB004 in 840 adults aged 40 and older in China. Participants receive one of four different doses of the vaccine or a placebo. The goal is to see how well the vaccine triggers an immune response and whether it is safe.

This study tests a vaccine called Triplex to prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. CMV is usually harmless but can be life-threatening for people with weakened immune systems. The vaccine uses harmless virus pieces to train th…

This early-stage trial tests an mRNA vaccine called BNT163, designed to prevent genital herpes caused by HSV-2 and possibly HSV-1. About 318 healthy adults and people with recurrent genital herpes will receive the vaccine or a placebo. The main goal is to check safety and measure…

This phase 2 study tests a new shingles vaccine called CRV-101 (amezosvatein) against the current standard, Shingrix, in about 1,500 adults aged 50 and older. The goal is to see if CRV-101 is safer and triggers a strong immune response. Participants receive two shots and are moni…

This early-stage trial is testing an experimental mRNA vaccine called mRNA-1195 to see if it is safe and triggers an immune response against Epstein-Barr virus (EBV). The study involves 482 healthy adults aged 18 to 55, some of whom have had EBV before and some who have not. Part…

This trial tests whether specially modified T cells from a partially matched donor can help patients recover their immune system faster after a stem cell transplant. The T cells are engineered with a 'suicide gene' that allows doctors to destroy them if they cause graft-versus-ho…

This study offers kidney transplant patients with antibody-mediated rejection (AMR) the chance to receive felzartamab for up to 4 more years. AMR occurs when the immune system attacks the new kidney. The main goal is to check long-term safety and monitor kidney health through bio…

This study tests whether specially grown immune cells can fight three common viruses—adenovirus, CMV, and EBV—in people whose immune systems are weak due to a stem cell or organ transplant, or an inherited immune disorder. The cells are made from a donor's blood and trained to re…

This phase 2 trial tests a drug called VK-2019 in 13 patients with Epstein-Barr virus (EBV)-positive nasopharyngeal cancer that has returned or spread and has no standard treatment. VK-2019 works by blocking a key viral protein, EBNA1, which the virus needs to survive. The main g…

This study tests whether a blood test for Epstein-Barr virus (EBV) DNA can help doctors choose the best chemotherapy after standard radiation for nasopharyngeal cancer. About 685 patients will first receive standard chemoradiation. Then, based on whether EBV DNA is still detectab…

This phase 2 trial tests whether immune cells from donors who have been exposed to CMV can treat persistent CMV infections in patients who have had a stem cell transplant. The study includes 49 participants with CMV that hasn't improved with standard antiviral drugs. The cells ar…

This study looks at a rare disease called KSHV-associated multicentric Castleman's disease (MCD), caused by a virus. Researchers are testing several drug combinations, including chemotherapy and antivirals, to see if they can control the disease. The study also tracks how the dis…

This study tests an experimental cell therapy called tabelecleucel in 190 people with diseases caused by the Epstein-Barr virus (EBV), including certain lymphomas and post-transplant complications. The treatment uses specially prepared immune cells to fight the virus. The main go…

This early-phase study tests a new treatment for advanced osteosarcoma and neuroblastoma that has not responded to standard therapy. Researchers take a patient's own immune cells (T cells), add a gene to help them recognize and attack cancer cells, and combine them with a chicken…

This study tests whether a newer drug, letermovir, works better and causes fewer side effects than the standard drug valganciclovir for preventing CMV infection in African American kidney transplant recipients. About 30 high-risk patients will take letermovir for 6 months after t…

This study looks at whether the shingles vaccine is safe and works well in young adults (19 and older) who have had a solid organ transplant. About 80 participants will get two doses of the vaccine and be monitored for side effects and immune response. The goal is to help protect…

This study looks at whether a special team of doctors and nurses can treat adults with suspected infections at home, instead of sending them to the hospital. About 500 people will be randomly assigned to either standard hospital care or home-based care from a mobile response team…

This study looks at two different approaches to prevent cytomegalovirus (CMV) infection in people who have received a kidney transplant from a living donor. The participants are at intermediate risk for CMV and are given standard anti-rejection medication. The goal is to see whic…

This study aimed to test an experimental virus therapy called G207, combined with a single dose of radiation, in children whose high-grade glioma had come back after prior treatment. The virus was injected directly into the brain tumor to kill cancer cells and trigger an immune r…

This study tests an experimental drug called brincidofovir in people with lymphoma (a type of blood cancer) that has returned or not improved after standard treatments. The trial has two parts: first, finding a safe dose in up to 18 people with various lymphomas, then testing tha…

This study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…

This phase II trial is testing whether giving the immunotherapy drug pembrolizumab before standard chemotherapy and radiation can help prevent stomach cancer from coming back. It includes 40 people with operable stomach cancer that has either a specific DNA repair problem (mismat…

This study tests whether a CMV-specific T cell immunity test can help doctors decide how long to give letermovir to prevent late CMV infection after a stem cell transplant. About 250 adults with blood cancers who had a first transplant will take part. The goal is to see if using …

This study tests a new way to treat viral infections that often occur after a solid organ transplant. Researchers create special immune cells, called viral-specific T-cells, from the patient's own blood to fight the virus. The goal is to reduce the need for strong anti-viral drug…

This study looks at how well the Shingrix vaccine protects against shingles in people over 50 living with HIV, compared to healthy adults of the same age and gender. About 225 participants will receive two doses of the vaccine and be monitored for one year. The goal is to see if …

This study tests the Shingrix vaccine in over 2,000 adults with autoimmune rheumatic diseases like rheumatoid arthritis and lupus, who are at higher risk for shingles. Researchers will compare vaccinated patients to unvaccinated ones to see if the vaccine is safe and triggers a s…

This early-phase study tests whether vaccinating stem cell donors against cytomegalovirus (CMV) can prevent the virus from causing problems in blood cancer patients after a transplant. About 34 donor-recipient pairs are taking part. The vaccine is given to the donor before stem c…

This study tests whether injecting a mix of lidocaine and steroids into tender points can better relieve shingles pain compared to standard painkillers alone. The trial involves 136 adults with severe shingles pain for less than 90 days. Researchers will track pain levels for up …

This study looks at HIV-negative people who get opportunistic infections—illnesses that usually only affect those with weak immune systems. Researchers want to find out if these patients have unusual antibodies that block a key immune signal. Up to 224 adults in Thailand and Taiw…

This study looks at how the immune system of patients in the intensive care unit (ICU) responds to severe infections caused by viruses or bacteria. Researchers will take extra blood samples from 38 adults to analyze immature granulocytes, a type of immune cell. The goal is to see…

This study tracks 56 follicular lymphoma patients to see how long their COVID-19 and other vaccine immunity lasts while they receive chemotherapy and maintenance therapy. Researchers will collect blood samples at several time points to measure immune responses. The goal is to und…

This study follows about 100 healthy adults aged 18 to 29 who have had Epstein-Barr virus (EBV) in the past. Researchers collect blood and saliva samples over 6 to 12 months to see when the virus becomes active again and how the immune system responds. No treatments or vaccines a…

This study looks at how the Shingrix vaccine, which protects against shingles, affects immune cells in the skin and blood. Researchers will give the vaccine to 50 healthy adults in two age groups: 30-40 years old and 70 years or older. They will measure specific antibodies and T-…

This study looks back at medical records of 50 adults who had a shingles virus infection in their brain or spinal cord. Researchers want to find out what makes some people more likely to get these serious infections and what leads to long-term problems like memory loss or seizure…

This study aimed to see if a computer could learn to predict how long a patient would stay in a home hospital program. Researchers planned to use data from past patients to train the computer. However, the study was withdrawn before any patients were enrolled, so no results are a…

This study is for adults receiving a kidney, lung, liver, or heart transplant. It will collect blood and tissue samples to learn how the body responds to CMV, a common virus that can cause serious problems after transplant. The goal is to better understand the virus and improve f…

This study looks at whether the shingles vaccine (HZ/su) is safe for pregnant women aged 18-49 with weakened immune systems. Researchers will track about 2,800 women to see if the vaccine raises the risk of birth defects or other problems in their babies. The goal is to provide r…

This study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…